Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-06-03
1999-10-26
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435375, 4353201, 424 932, 424 9321, 514 2, 536 231, 536 245, A61K 4800, C12N 1509, C12N 1563, C07H 2104
Patent
active
059729007
ABSTRACT:
Nucleic acids are compacted, substantially without aggregation, to facilitate their uptake by target cells of an organism to which the compacted material is administered. The nucleic acids may achieve a clinical effect as a result of gene expression, hybridization to endogenous nucleic acids whose expression is undesired, or site-specific integration so that a target gene is replaced, modified or deleted. The targeting may be enhanced by means of a target cell-binding moiety. The nucleic acid is preferably compacted to a condensed state.
REFERENCES:
patent: 5108921 (1992-04-01), Low et al.
patent: 5149782 (1992-09-01), Chang et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5354844 (1994-10-01), Beug et al.
patent: 5521291 (1996-05-01), Curiel et al.
Wagner et al., Proc. Natl. Acad. Sci., 88:4255-4259 (1991).
Dubneski et al., Proc. Nat. Acad. Sci. USA, 81:7529-33 (1984).
Benvenisty and Reshef, Proc. Nat. Acad. Sci. USA, 83:9551-55 (1986).
Wolff et al., Science, 247:1456-68 (1990).
Acsadi et al., New Biologist, 3:71-81 (1991).
Ennever et al., Biochem. Biophys. Acta, 826:67 (1985).
Miller, P.S. et al., Biochemistry 20:1874-1880 (1981).
Miller et al., Biochemistry, 18:5134-43 (1979).
Matsukura et al., Proc. Nat. Acad. Sci., 84:7706-10 (1987).
Zerial et al., Nucleic Acids Res., 15:9909-19 (1987).
Leonetti et al., Gene, 72:32-33 (1988).
Schlepper-Schafer, J. et al., Exp. Cell. Res. 165:494 (1986).
Bijsterbosch, M.K. et al., Mol. Pharmacol 36:484 (1989).
Bijsterbosch, M.K. et al., Mol. Pharmacol 41:404 (1992).
Chen et al., "Design of a genetic immunotoxin to eliminate toxin immunogenicity," Gene Therapy 2:116 (1995).
Barinaga, "Step Taken Toward Improved Vectors for Gene Transfer," Science 266:1326 (1994).
Shin et al., "Transferrin-antibody fusion proteins are effective in brain targeting," Proc. Nat. Acad. Sci. 92:2820 (1995).
Shin and Morrison, "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," Proc. Nat. Acad. Sci. 87:5322 (1990).
Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake," Proc. Nat. Acad. Sci. 87:3410 (1990).
Zenke et al., "Receptor-mediated endocytosis of transferrin-polycation conjugates: An efficient way to introduce DNA into hematopoietic cells," Proc. Nat. Acad. Sci. 87:3655 (1990).
Ferkol et al., "Targeted Gene Delivery To Respiratory Epithelial Cells," Abstract at 1992 Cystic Fibrosis Conference.
T. Ferkol et al., "Gene Transfer into the Airway Epithelium of Animals by Targeting the Polymeric Immunoglobulin Receptor," J. Clin. Invest. 95:493 (Feb. 1995).
Marshall, Science 269: 1050-1055, 1995.
Orkin et al. , NIH "Report and Recommendations . . . ".
Laemmli, PNAS 72(11): 4288-4292, 1973.
Kaetzel et al. PNAS 8: 8796-8800, 1991.
Wagner et al., PNAS 77: 4255-4259, 1991.
Midoux et al., Nuc. Acids Res. 21(4): 871-878, 1993.
Ferkol et al., PNAS 93(1): 101-105, 1996.
Orkin et al., "Report and Recommendations . . . " Dec. 7, 1995, 1-40.
Davis Pamela B.
Ferkol, Jr. Thomas W.
Case Western Reserve University
Hauda Karen M.
Stanton Brian R.
LandOfFree
Delivery of nucleic acid to cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of nucleic acid to cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of nucleic acid to cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764546